IntegraGen SA (ALINT.PA)

EUR 0.53

(0.0%)

Total Liabilities Summary of IntegraGen SA

  • IntegraGen SA's latest annual total liabilities in 2023 was 5.97 Million EUR , down -12.35% from previous year.
  • IntegraGen SA's latest quarterly total liabilities in 2024 Q2 was 4.32 Million EUR , down 0.0% from previous quarter.
  • IntegraGen SA reported annual total liabilities of 6.82 Million EUR in 2022, down -8.03% from previous year.
  • IntegraGen SA reported annual total liabilities of 7.41 Million EUR in 2021, up 11.55% from previous year.
  • IntegraGen SA reported quarterly total liabilities of 8.82 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • IntegraGen SA reported quarterly total liabilities of 5.97 Million EUR for 2023 FY, down -12.35% from previous quarter.

Annual Total Liabilities Chart of IntegraGen SA (2023 - 2008)

Historical Annual Total Liabilities of IntegraGen SA (2023 - 2008)

Year Total Liabilities Total Liabilities Growth
2023 5.97 Million EUR -12.35%
2022 6.82 Million EUR -8.03%
2021 7.41 Million EUR 11.55%
2020 6.65 Million EUR 56.88%
2019 4.23 Million EUR -26.77%
2018 5.78 Million EUR 22.68%
2017 4.71 Million EUR -25.18%
2016 6.3 Million EUR 10.91%
2015 5.68 Million EUR 5.16%
2014 5.4 Million EUR 6.2%
2013 5.09 Million EUR 10.3%
2012 4.61 Million EUR 19.14%
2011 3.87 Million EUR 27.16%
2010 3.04 Million EUR 4.81%
2009 2.9 Million EUR 38.75%
2008 2.09 Million EUR 0.0%

Peer Total Liabilities Comparison of IntegraGen SA

Name Total Liabilities Total Liabilities Difference
ABIONYX Pharma SA 6.91 Million EUR 13.487%
ABIVAX Société Anonyme 131.05 Million EUR 95.437%
Adocia SA 31.87 Million EUR 81.237%
Aelis Farma SA 13.08 Million EUR 54.283%
Biophytis S.A. 15.84 Million EUR 62.27%
Advicenne S.A. 24.37 Million EUR 75.47%
genOway Société anonyme 14.45 Million EUR 58.645%
Medesis Pharma S.A. 6.42 Million EUR 6.946%
Neovacs S.A. 3.71 Million EUR -61.088%
NFL Biosciences SA 3.62 Million EUR -65.157%
Plant Advanced Technologies SA 6.78 Million EUR 11.833%
Quantum Genomics Société Anonyme 3.31 Million EUR -80.653%
Sensorion SA 13.22 Million EUR 54.792%
Theranexus Société Anonyme 5.01 Million EUR -19.21%
TME Pharma N.V. 2.78 Million EUR -114.714%
Valbiotis SA 13.7 Million EUR 56.377%
TheraVet SA 1.48 Million EUR -302.682%
Valerio Therapeutics Société anonyme 20.46 Million EUR 70.785%
argenx SE 402.79 Million EUR 98.515%
BioSenic S.A. 32.26 Million EUR 81.466%
Celyad Oncology SA 9.97 Million EUR 40.07%
DBV Technologies S.A. 38.74 Million USD 84.566%
Galapagos NV 1.56 Billion EUR 99.617%
Genfit S.A. 105.92 Million EUR 94.354%
GeNeuro SA 20.13 Million EUR 70.309%
Hyloris Pharmaceuticals SA 8.61 Million EUR 30.564%
Innate Pharma S.A. 132.29 Million EUR 95.48%
Inventiva S.A. 101.59 Million EUR 94.114%
MaaT Pharma SA 22.46 Million EUR 73.382%
MedinCell S.A. 77.77 Million EUR 92.311%
Nanobiotix S.A. 95.74 Million EUR 93.754%
Onward Medical N.V. 25.69 Million EUR 76.73%
Oryzon Genomics S.A. 25.12 Million EUR 76.2%
OSE Immunotherapeutics SA 59.07 Million EUR 89.878%
Oxurion NV 19.73 Million EUR 69.701%
Pharming Group N.V. 228.28 Million EUR 97.381%
Poxel S.A. 53.9 Million EUR 88.906%
GenSight Biologics S.A. 34.72 Million EUR 82.781%
Transgene SA 26.51 Million EUR 77.449%
Financière de Tubize SA 123.65 Million EUR 95.164%
UCB SA 6.56 Billion EUR 99.909%
Valneva SE 341.14 Million EUR 98.247%
Vivoryon Therapeutics N.V. 4.54 Million EUR -31.511%